<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02451579</url>
  </required_header>
  <id_info>
    <org_study_id>PDT-2015-01</org_study_id>
    <nct_id>NCT02451579</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goldman, Butterwick, Fitzpatrick and Groff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DUSA Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Goldman, Butterwick, Fitzpatrick and Groff</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, placebo controlled study conducted at a single study site. Evaluating the
      role of systemic antihistamine therapy in the reduction of adverse effects associated with
      topical 5-aminolevulinic acid photodynamic therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Localized Skin Response</measure>
    <time_frame>Up to day 180</time_frame>
    <description>Localized Skin Response consisting of erythema, edema, crusting, exudation, Vesiculation/Pustulation and erosion/ ulceration Investigator evaluated on a standardized scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>Cetirizine Hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prophylactic use of cetirizine hydrochloride prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Prophylactic use of placebo prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antihistamine Cetirizine Hydrochloride</intervention_name>
    <description>Prophylactic use of antihistamine prior to and following topical 5-aminolevulonic acid photodynamic therapy</description>
    <arm_group_label>Cetirizine Hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Use of placebo prior to and following topical 5-aminolevulonic acid photodynamic therapy</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18

          -  Subjects with 5-20 actinic keratosis of the face

          -  Patients undergoing photodynamic therapy (PDT) to the face for AK with
             5-aminolevulinic acid (ALA) activated by blue light.

          -  Must be willing to give and sign a HIPPA form, photo consent and informed consent
             form.

          -  Must be willing to comply with study dosing and complete the entire course of the
             study.

          -  Female patients will be either of non-childbearing potential defined as:

               1. Having no uterus

               2. No menses for at least 12 months.

        Or;

        (WOCBP) women of childbearing potential must agree to use an effective method of birth
        control during the course of the study, such as:

          1. Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device

          2. Intrauterine coil

          3. Bilateral tubal ligation

          4. Barrier method used with an additional form of contraception (e.g., sponge, spermicide
             or condom)

          5. Abstinence (If practicing abstinence must agree to use barrier method described above
             (d) if becomes sexually active).

          6. Vasectomized partner g. Negative urine pregnancy test results Baseline prior to study
             entry (if applicable)

        Exclusion Criteria:

          -  Presence of incompletely healed wound in treatment area

          -  Presence of known or suspected BCC or SCC in treatment area

          -  Previous PDT or treatment of the face with any topical cytotoxic or immunomodulatory
             agent for AKs within the past 6 months

          -  Co-existing potentially confounding skin condition within treatment area (e.g. eczema,
             psoriasis, XP, rosacea) at investigator's discretion

          -  Presence of tattoo and/or scar in the treatment area that in the investigators opinion
             would interfere with study assessments

          -  Subjects with known photosensitivity or taking photosensitizing medications listed
             below:

               1. Oral diabetes medicines

               2. Griseofulvin

               3. Thiazide diuretics

               4. Sulfonylureas

               5. Phenothiazines

               6. Tetracycline's

               7. St. John's Wort

          -  Use of oral/topical retinoids within 1 month of Baseline

          -  Subjects with a history of sensitivity to porphyrins

          -  Subjects with recently excessive exposure of the treatment area to sunlight or
             artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing) or
             expectations of tanning during the time of the study

          -  Female subjects who are pregnant, nursing an infant or planning a pregnancy during the
             study [throughout the course of the study

          -  Presence or evidence of any conditions that in the opinion of the investigator might
             impede the subject's ability to give consent or comply with protocol requirements.

          -  Current participation or participation within 30 days prior to the start of this study
             in a drug or other investigational research study

          -  History of non-compliance with clinical research protocols

          -  Ablative laser resurfacing to on their face within 12 months

          -  Non-ablative laser or light procedures to their face within the past 3 months

          -  Microdermabrasion (light or medium skin peel) treatment on their face within the past
             30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchel P Goldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cosmetic Laser Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cosmetic Laser Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratoses</keyword>
  <keyword>Photodynamic Therapy</keyword>
  <keyword>PDT</keyword>
  <keyword>Blue Light</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Histamine Antagonists</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

